The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib

Autor: Caputo F., Dadduzio V., Tovoli F., Bertolini G., Cabibbo G., Cerma K., Vivaldi C., Faloppi L., Rizzato M. D., Piscaglia F., Celsa C., Fornaro L., Marisi G., Conti F., Silvestris N., Silletta M., Lonardi S., Granito A., Stornello C., Massa V., Astara G., Delcuratolo S., Cascinu S., Scartozzi M., Casadei-Gardini A.
Přispěvatelé: Francesco Caputo,Vincenzo Dadduzio,Francesco Tovoli,Giulia Bertolini,Giuseppe Cabibbo,Krisida Cerma,Caterina Vivaldi,Luca Faloppi,Mario Domenico Rizzato,Fabio Piscaglia,Ciro Celsa,Lorenzo Fornaro,Giorgia Marisi,Fabio Conti,Nicola Silvestris,Marianna Silletta,Sara Lonardi,Alessandro Granito,Caterina Stornello,Valentina Massa,Giorgio Astara,Sabina Delcuratolo,Stefano Cascinu,Mario Scartozzi,Andrea Casadei-Gardini, Caputo, F., Dadduzio, V., Tovoli, F., Bertolini, G., Cabibbo, G., Cerma, K., Vivaldi, C., Faloppi, L., Rizzato, M. D., Piscaglia, F., Celsa, C., Fornaro, L., Marisi, G., Conti, F., Silvestris, N., Silletta, M., Lonardi, S., Granito, A., Stornello, C., Massa, V., Astara, G., Delcuratolo, S., Cascinu, S., Scartozzi, M., Casadei Gardini, A., Caputo F., Dadduzio V., Tovoli F., Bertolini G., Cabibbo G., Cerma K., Vivaldi C., Faloppi L., Rizzato M.D., Piscaglia F., Celsa C., Fornaro L., Marisi G., Conti F., Silvestris N., Silletta M., Lonardi S., Granito A., Stornello C., Massa V., Astara G., Delcuratolo S., Cascinu S., Scartozzi M., Casadei-Gardini A.
Jazyk: angličtina
Rok vydání: 2020
Předmět:
RNA viruses
Male
Etiology
Cancer Treatment
Hepacivirus
Kaplan-Meier Estimate
Biochemistry
Cohort Studies
White Blood Cells
Mathematical and Statistical Techniques
Retrospective Studie
Animal Cells
Adult
Aged
Aged
80 and over
Antineoplastic Agents
Carcinoma
Hepatocellular
Female
Humans
Italy
Liver Neoplasms
Lymphocyte Count
Middle Aged
Prognosis
Retrospective Studies
Serum Albumin
Sorafenib
Nutrition Assessment
Medicine and Health Sciences
80 and over
Lymphocytes
Pathology and laboratory medicine
Hepatitis C virus
Liver Diseases
Statistics
Medical microbiology
Oncology
Liver Neoplasm
Physical Sciences
Viruses
Medicine
Pathogens
Cellular Types
Human
Research Article
Hepatitis B virus
Immune Cells
Science
Immunology
Gastroenterology and Hepatology
Research and Analysis Methods
Carcinomas
Microbiology
Albumins
Gastrointestinal Tumors
Statistical Methods
Blood Cells
Adult
Aged
80 and over
Antineoplastic Agents
Carcinoma
Hepatocellular
Cohort Studies
Female
Humans
Italy
Kaplan-Meier Estimate
Liver Neoplasms
Lymphocyte Count
Male
Middle Aged
Prognosis
Retrospective Studies
Serum Albumin
Sorafenib
Nutrition Assessment
Biology and life sciences
Flaviviruses
Carcinoma
Viral pathogens
Organisms
Cancers and Neoplasms
Proteins
Hepatocellular
Hepatocellular Carcinoma
Cell Biology
prognostic nutritional index (PNI)
hepatocellular carcinoma (HCC)
sorafenib.
survival
mRECIST
Hepatitis viruses
Microbial pathogens
Multivariate Analysis
Cohort Studie
Mathematics
Zdroj: PLoS ONE, Vol 15, Iss 5, p e0232449 (2020)
PLoS ONE
Popis: Background and aims The present study aims to investigate the role of the prognostic nutritional index (PNI) on survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. Methods This multicentric study included a training cohort of 194 HCC patients and three external validation cohorts of 129, 76 and 265 HCC patients treated with Sorafenib, respectively. The PNI was calculated as follows: 10 × serum albumin (g/dL) + 0.005 × total lymphocyte count (per mm3). Univariate and multivariate analyses were performed to investigate the association between the covariates and the overall survival (OS). Results A PNI cut-off value of 31.3 was established using the ROC analysis. In the training cohort, the median OS was 14.8 months (95% CI 12–76.3) and 6.8 months (95% CI 2.7–24.6) for patients with a high (>31.3) and low ( 70 years (p< 0.0038) were independent prognostic factors for OS. By performing the same multivariate analysis of the training cohort, the PNI 31.3 was found to be an independent prognostic factor for predicting OS in all the three validation cohorts. Conclusions PNI represents a prognostic tool in advanced HCC treated with first-line Sorafenib. It is readily available and low-cost, and it could be implemented in clinical practice in patients with HCC.
Databáze: OpenAIRE
Externí odkaz: